Issue of Options

(AIM: SAR)

19 December 2013

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Issue of Options

The Company announces that it has granted the following share options (the "Options") to Tim Mitchell, Chief Executive Officer, John Reader, Chief Scientific Officer and Paul Harper, Non-Executive Chairman (together, the "Directors");

	Number of options
Tim Mitchell	4,752,000
John Reader	4,752,000
Paul Harper	810,000

The Options have been granted with an exercise price of 0.6 pence and are exercisable until 18 December 2023.

Of the Options granted to each Director, 34% will vest immediately, with the remaining 66% vesting subject to pre-determined performance criteria.

In addition to the Options being granted, Tim Mitchell and John Reader currently each hold the following options:

Exercise period	Number of options	Exercise price
4 December 2009 - 4 December 2019	6,400,000	0.25 pence
22 December 2010 - 22 December 2020	6,153,846	0.26 pence
13 March 2012 - 13 March 2022	2,566,666	1.2 pence

Enquires:

Sareum Holdings plc
Tim Mitchell, Chief Executive Officer	01223 497 700
Sanlam Securities UK Limited (Nominated Adviser)
Simon Clements	020 7628 2200
Hybridan LLP (Broker)
Claire Noyce / William Lynne	020 7947 4350 / 4361
The Communications Portfolio (Media enquiries)
Ariane Comstive [e-mail]	020 7536 2028 / 2029

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

For further information, please visit www.sareum.co.uk

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SAREUM HOLDINGS PLC via Globenewswire

HUG#1750972